Avant Technologies, Inc. Bolsters Strategic Vision with Targeted Biotech Partnerships for Innovative Cell-Based Therapies
Avant Technologies (OTCQB: AVAI) announced a strategic shift towards partnership-driven biotechnology development through joint ventures and licensing agreements. The company is focusing on advancing treatments for chronic and age-related conditions including diabetes, Alzheimer's, heart disease, cancer, and kidney disease.
The company's strategy involves collaborating with biotech firms specializing in genetically modified cell lines and partnering with a global cell-encapsulation technology company. Their first joint venture with Ainnova Tech incorporates Vision AI for non-invasive disease detection, while their latest venture focuses on developing cell line therapy for Klotho protein production, crucial for aging and disease processes.
Avant Technologies (OTCQB: AVAI) ha annunciato una svolta strategica orientata allo sviluppo biotecnologico basato su partnership, tramite joint venture e accordi di licenza. L'azienda si concentra sul progresso di trattamenti per condizioni croniche e legate all'invecchiamento, tra cui diabete, Alzheimer, malattie cardiache, cancro e malattie renali.
La strategia prevede collaborazioni con aziende bio-tecnologiche specializzate in linee cellulari geneticamente modificate e il partenariato con una società globale di tecnologia di incapsulamento cellulare. La loro prima joint venture con Ainnova Tech integra l'Intelligenza Visiva per il rilevamento non invasivo delle malattie, mentre l'ultima iniziativa si concentra sullo sviluppo di una terapia a base di linee cellulari per la produzione di proteina Klotho, cruciale nei processi di invecchiamento e di malattia.
Avant Technologies (OTCQB: AVAI) anunció un cambio estratégico hacia el desarrollo biotecnológico impulsado por asociaciones, mediante joint ventures y acuerdos de licencia. La empresa se centra en avanzar tratamientos para condiciones crónicas y relacionadas con la edad, incluyendo diabetes, Alzheimer, enfermedad cardíaca, cáncer y enfermedad renal.
La estrategia de la empresa implica colaborar con compañías de biotecnología especializadas en líneas celulares genéticamente modificadas y asociarse con una empresa global de tecnología de encapsulación celular. Su primera joint venture con Ainnova Tech incorpora IA visual para la detección no invasiva de enfermedades, mientras que su último emprendimiento se centra en desarrollar una terapia de líneas celulares para la producción de la proteína Klotho, crucial para el envejecimiento y los procesos de enfermedad.
Avant Technologies (OTCQB: AVAI)는 파트너십 기반의 바이오테크 개발으로의 전략적 전환을 발표했습니다. 이 회사는 당뇨병, 알츠하이머, 심장병, 암, 신장질환 등 만성 및 노화 관련 질환 치료의 진전에 집중하고 있습니다.
회사의 전략은 유전자 변형 세포주를 전문으로 하는 바이오테크 기업과 협력하고, 전 세계 세포 캡슐화 기술 회사와의 파트너십을 포함합니다. Ainnova Tech와의 첫 합작투자는 질병 비침습적 탐지를 위한 Vision AI를 통합하고, 최근의 벤처는 노화 및 질병 과정에 중요한 Klotho 단백질 생산을 위한 세포주 치료 개발에 중점을 두고 있습니다.
Avant Technologies (OTCQB: AVAI) a annoncé une réorientation stratégique vers un développement biotechnologique axé sur les partenariats, via des coentreprises et des accords de licence. L'entreprise se concentre sur l'avancement de traitements pour des affections chroniques et liées à l'âge, notamment le diabète, Alzheimer, maladies cardiaques, cancer et maladie rénale.
La stratégie de l'entreprise consiste à collaborer avec des sociétés biotech spécialisées dans les lignes cellulaires génétiquement modifiées et à s'associer à une société mondiale de technologie d'encapsulation cellulaire. Leur premier joint-venture avec Ainnova Tech intègre l'IA visuelle pour la détection non invasive des maladies, tandis que leur dernier projet se concentre sur le développement d'un thérapie par lignes cellulaires pour la production de la protéine Klotho, cruciale pour les processus de vieillissement et de maladie.
Avant Technologies (OTCQB: AVAI) kündigte eine strategische Neuausrichtung hin zu einer partnershipsorientierten biotechnologischen Entwicklung durch Joint Ventures und Lizenzvereinbarungen an. Das Unternehmen konzentriert sich darauf, Behandlungen für chronische und alterungsbezogene Erkrankungen wie Diabetes, Alzheimer, Herzkrankheiten, Krebs und Nierenerkrankungen voranzutreiben.
Die Strategie des Unternehmens sieht die Zusammenarbeit mit Biotech-Firmen vor, die sich auf genetisch modifizierte Zelllinien spezialisiert haben, sowie die Partnerschaft mit einem globalen Zell-Einbettungstechnologieunternehmen. Ihr erstes Joint Venture mit Ainnova Tech integriert Vision AI für die nicht-invasive Krankheitsdiagnose, während ihr jüngstes Vorhaben sich auf die Entwicklung einer Zelllinien-Therapie zur Produktion von Klotho-Protein konzentriert, das für Alterungsprozesse und Krankheiten entscheidend ist.
Avant Technologies (OTCQB: AVAI) أعلنت عن تحول استراتيجي نحو تطوير بيوتكنولوجي يعتمد على الشراكات من خلال مشاريع مشتركة واتفاقيات ترخيص. تركّز الشركة على تعزيز العلاجات للحالات المزمنة والمتعلقة بالعمر بما في ذلك مرض السكري، والزهايمر، وأمراض القلب، والسرطان، وأمراض الكلى.
استراتيجيتها تتضمن التعاون مع شركات بيوتك متخصصة في خطوط الخلايا المعدلة وراثياً والشراكة مع شركة عالمية في تكنولوجيا تغليف الخلايا. أول مشروع مشترك لها مع Ainnova Tech يدمج Vision AI للكشف عن الأمراض غير الجراحية، بينما يركّز أحدث مشروع على تطوير علاج خط خلوي لإنتاج بروتين كلوتو، وهو أمر حيوي لعمليات الشيخوخة والأمراض.
Avant Technologies (OTCQB: AVAI) 宣布通过合资企业和许可协议的伙伴关系驱动的生物技术开发的战略转变。公司专注于推进慢性和与年龄相关疾病的治疗，包括糖尿病、阿尔茨海默病、心脏病、癌症和肾脏病。
公司策略包括与专注于基因改造细胞系的生物技术公司合作，并与全球细胞封装技术公司建立伙伴关系。他们与Ainnova Tech的第一家合资企业将视像AI用于非侵入性疾病检测，而他们最新的合资企业聚焦于开发用于Klotho蛋白生产的细胞系疗法，这对衰老和疾病过程至关重要。
- None.
- Early stage of partnerships with no proven revenue streams yet
- Operating in highly competitive and regulated biotech space
- Success dependent on partners' performance and technology viability
This new model positions Avant at the forefront of collaborative biotech innovation, identifying promising cell lines from around the globe and forging alliances with leading biotech companies, scientists, and clinicians. By partnering rather than bearing the full burden of development costs and risks, Avant and its partners leverage complementary expertise and resources to accelerate the creation of groundbreaking therapies. Key areas of focus include diabetes, anti-aging, Alzheimer's disease, heart disease, cancer, kidney disease, other age-related conditions, and the promotion of longevity.
Central to Avant's approach are partnerships with biotech companies specializing in genetically modified cell lines designed to perform essential functions within the body that may be deficient in patients. Additionally, the company is collaborating with a leading global cell-encapsulation technology firm to safeguard these cells during therapeutic applications, ensuring their efficacy and safety in development programs.
"Our transition to a partnership-driven model represents a transformative step for Avant, enabling us to harness global innovations in cell therapy while mitigating traditional development challenges," said Chris Winter, Chief Executive Officer of Avant. "By combining forces with top-tier experts, we're not just identifying diseases - we're actively developing solutions that could change lives."
Highlighting this strategy, Avant's first joint venture with Ainnova Tech, Inc. integrates its advanced Vision AI platform to detect a spectrum of diseases, including diabetes-related complications, through non-invasive diagnostics. Building on this, the company's latest joint venture focuses on developing a cell line therapy that produces the Klotho protein, a key regulator in aging and disease processes. Future collaborations will expand these efforts, creating a robust pipeline to both identify and treat serious illnesses.
This unique ecosystem of joint ventures empowers Avant to bridge the gap between disease detection and targeted treatment, fostering rapid advancements in personalized medicine.
About Avant Technologies Inc.
Avant Technologies Inc. is dedicated to advancing health through strategic biotech partnerships, focusing on innovative cell-based therapies and AI-driven diagnostics to combat chronic and age-related diseases and promote longevity.
More information about Avant can be found at https://avanttechnologies.com
You can also follow us on social media at:
https://twitter.com/AvantTechAI
https://www.facebook.com/AvantTechAI
https://www.youtube.com/@AvantTechAI
Forward-Looking Statements
Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company's ability to raise capital on acceptable terms, if at all, the Company's successful development of its products and the integration into its existing products and the commercial acceptance of the Company's products. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date after the date of the press release.
Contact:
Avant Technologies Inc.
info@avanttechnologies.com
Logo: https://mma.prnewswire.com/media/2370694/5530320/Avant_Technologies.jpg
View original content:https://www.prnewswire.com/news-releases/avant-technologies-inc-bolsters-strategic-vision-with-targeted-biotech-partnerships-for-innovative-cell-based-therapies-302566991.html
SOURCE Avant Technologies Inc.
FAQ
What is Avant Technologies' (AVAI) new business strategy?
What therapeutic areas is Avant Technologies (AVAI) targeting?
Who are Avant Technologies' (AVAI) current strategic partners?
How does Avant Technologies' (AVAI) partnership model work?
What is the significance of Avant's Klotho protein therapy development?
